Gifu University Hospital and our company have started joint research on N-NOSE. This study examines the usefulness of “N-NOSE” cancer risk assessment in the treatment of solid tumors (esophagus, stomach, large intestine, pancreas, milk). Both sides will work on this research with the expectation that “N-NOSE” will go beyond the framework of screening tests and be established as an important test method in clinical practice.
HIROTSU BIO SCIENCE Corporation is proud to announce the opening of a store on Tmall Global, the largest cross-border EC platform in China opera . . .2023.08.22
Hirotsu Bio Science Inc. (Headquarters: Chiyoda-ku, Tokyo, Representative Director: Takaaki Hirotsu) has signed a memorandum of understanding wi . . .2023.06.13
On Thursday, March 16, "DAVOS 2023 DEBRIEFING" was held by the Consulate of Switzerland in Osaka.Our CMO/CGO, Shunsuke Mizushima, was invited as . . .2023.03.20